Clinical Trials Brief | July 13, 2026
This week: the largest ATTR-CM outcomes trial to date missing its primary endpoint when an RNA silencer was added on top of stabilisers, FDA granting accelerated approval to the first BAFF/APRIL inhibitor for IgA nephropathy on a proteinuria surrogate, PRAC bringing Litfulo into line with the JAK inhibitor class warnings, PRAC confirming a small meningioma risk with prolonged desogestrel and etonogestrel use, and Vertex agreeing to buy Crinetics for about $10 billion.
CARDIO-TTRansform misses its primary endpoint, a hard lesson in testing add-on therapy against a moving standard of care
What changed
On July 9, 2026, AstraZeneca and Ionis announced that the Phase 3 CARDIO-TTRansform trial of eplontersen (Wainua) in transthyretin amyloid cardiomyopathy (ATTR-CM) did not meet its primary endpoint, a composite of cardiovascular mortality and recurrent cardiovascular events up to week 140 compared with placebo. The trial enrolled 1,432 participants at 130 sites in 20 countries, making it the largest ATTR-CM trial enrolled to date. Participants were on available standard of care: 57% in each arm were on a TTR stabiliser at baseline, and a further 24% in each arm started one during the trial. Ionis reported that several secondary, imaging and biomarker analyses favoured eplontersen, and that the safety profile was consistent with earlier studies. Full results were scheduled for a later congress presentation.
Why it matters
This is a global design lesson as much as a drug result. When a trial runs for nearly three years in a disease where effective background therapy is spreading, the control arm improves along with practice. By the end, roughly four in five participants in each arm had stabiliser exposure, which compresses the room for any add-on to show an outcome benefit. Analysts quoted by Benzinga read the result as support for monotherapy with newer agents rather than silencer-plus-stabiliser combinations, while noting it was surprising given earlier combination data from a competing silencer. For anyone running long outcome trials, the question is not only "does the drug work" but "against what background, and how will that background change during enrolment".
Takeaway
When background therapy is evolving, sponsors should model the uptake of standard care during the trial, not just at baseline, and size the study accordingly. Prespecified analyses by background-therapy status, ideally stratified at randomisation, are what allow a miss like this to still be interpretable. For cardiac amyloidosis specifically, the detailed congress data will be essential before drawing class-level conclusions.
Sources
This item is grounded in the AstraZeneca SEC filing and Ionis press release of July 9, 2026, with market reaction from Benzinga.
FDA grants accelerated approval to atacicept for IgA nephropathy on proteinuria, with the confirmatory eGFR readout already months away
What changed
On July 7, 2026, FDA granted accelerated approval to Trutakna (atacicept-vymj, Vera Therapeutics) to reduce proteinuria in adults with primary IgA nephropathy at risk of disease progression. It is a once-weekly 150 mg subcutaneous injection that patients can self-administer at home with an autoinjector, and it is the first approved inhibitor of both BAFF and APRIL in this disease. Approval was based on a prespecified interim analysis of the first 203 participants in the Phase 3 ORIGIN 3 trial: a 46% reduction from baseline in urine protein-to-creatinine ratio, and a 42% reduction versus placebo at 36 weeks. FDA notes that it has not been established whether atacicept slows long-term kidney function decline. ORIGIN 3 continues blinded and placebo-controlled to assess eGFR, with results expected in the third quarter of 2026.
Why it matters
IgA nephropathy has become the clearest example of the proteinuria-to-eGFR accelerated approval model: approve on a surrogate, confirm on kidney function from the same ongoing trial. Here the gap between the two is unusually short, which reduces the usual criticism that accelerated approvals leave clinical benefit unverified for years. It also shows why keeping the confirmatory trial blinded matters: once a drug is on the market, a placebo-controlled study is only feasible if it was already enrolled and running. The competitive field is crowded, with Novartis's Fabhalta and Otsuka's product approved and Vertex's povetacicept under review, according to BioSpace.
Takeaway
For sponsors in other surrogate-driven indications, ORIGIN 3 is a useful template: design one trial with a prespecified interim surrogate analysis for accelerated approval and a later clinical endpoint for confirmation, and protect the blind in between. The Q3 eGFR readout will show whether proteinuria reduction carries through, which matters for the whole BAFF/APRIL class.
Sources
This item is grounded in FDA's July 7, 2026 announcement, Vera Therapeutics' press release, and HCPLive and BioSpace reporting.
PRAC applies the JAK inhibitor class warnings to Litfulo, including a boxed warning, even without a dedicated outcomes trial
What changed
At its July 6-9, 2026 meeting, EMA's safety committee PRAC agreed a direct healthcare professional communication (DHPC) on Litfulo (ritlecitinib), used for severe alopecia areata in adults and adolescents over 12. A boxed warning will be added stating that Litfulo should be used only if no suitable alternatives exist in patients aged 65 or over, patients at increased risk of major cardiovascular problems, current or long-term past smokers, and patients at increased risk of cancer. It should also be used with caution in patients with other risk factors for venous thromboembolism. PRAC reviewed clinical trial data, the literature and spontaneous reports, and concluded that because ritlecitinib also inhibits a JAK enzyme (JAK3, along with TEC kinases), the same warnings that apply to other JAK inhibitors should apply. The recommendation goes to CHMP for adoption.
Why it matters
This is a mechanism-based class extension, similar in logic to the PRC2 decision covered in this brief in June: a risk established for some members of a class is applied to another member with a related mechanism, without waiting for a product-specific outcomes trial. Ritlecitinib's selectivity profile differs from the JAK inhibitors that generated the original cardiovascular and malignancy data, but the regulator has decided that difference is not enough to exempt it. For developers of more selective kinase inhibitors, this narrows the room to argue that selectivity alone justifies a cleaner label.
Takeaway
Trials of JAK-pathway drugs in dermatology should expect eligibility, monitoring and informed consent to reflect the class boxed warning from the start, including for adolescents. Sponsors claiming differentiation on selectivity will need direct comparative safety evidence, not mechanistic argument.
Sources
This item is grounded in EMA's PRAC meeting highlights for July 6-9, 2026, published July 10.
PRAC confirms a small meningioma risk with prolonged desogestrel and etonogestrel use and adds a contraindication
What changed
At the same July meeting, PRAC agreed a DHPC on a small increased risk of meningioma with current, prolonged use (more than one year) of contraceptives containing desogestrel or etonogestrel. EMA estimates one additional meningioma for every 67,300 women who use these medicines. They are now contraindicated in women who have, or have had, a meningioma, and must be stopped if one is diagnosed. Women should be monitored for symptoms such as changes in vision, hearing loss or tinnitus, loss of smell, worsening headaches, memory loss, seizures or limb weakness. The risk may be higher in women who previously used progestogens already linked to meningioma, such as cyproterone, nomegestrol, medroxyprogesterone and chlormadinone. The recommendation follows a large French national case-control study published in the BMJ in 2025. Product information will list meningioma with frequency "not known".
Why it matters
Desogestrel is a widely used progestogen-only pill, and etonogestrel is the hormone in contraceptive implants and, combined with ethinylestradiol, vaginal rings. That makes this a high-exposure, low-absolute-risk signal, which is the hardest kind to communicate without causing people to stop effective contraception. It also extends the progestogen-meningioma story beyond the high-dose agents where it was first established, and it originated from national health-data pharmacoepidemiology rather than spontaneous reports.
Takeaway
For clinical trials, the practical step is screening: protocols that allow or require hormonal contraception should consider meningioma history in eligibility and capture prior progestogen exposure in medication history. For neuro-oncology and neurology trials, contraceptive type is now a relevant covariate when meningioma is an outcome or incidental finding.
Sources
This item is grounded in EMA's PRAC meeting highlights for July 6-9, 2026, which cite Roland et al., BMJ 2025.
Vertex agrees to buy Crinetics for about $10 billion, adding an oral acromegaly launch and a Phase 3 CAH asset
What changed
On July 6, 2026, Vertex and Crinetics announced a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, a total equity value of approximately $10.0 billion, or about $8.8 billion net of estimated cash. Both boards approved the deal, which is expected to close in the third quarter of 2026. Crinetics markets Palsonify (paltusotine), the first once-daily oral treatment for adults with acromegaly, approved by FDA in September 2025. Its lead pipeline asset is atumelnant, a once-daily oral ACTH receptor antagonist in Phase 3 for congenital adrenal hyperplasia (CAH), which has also shown potential in Cushing's syndrome. Vertex describes the combined opportunity as about $5 billion in peak sales.
Why it matters
This is Vertex's largest acquisition and a move into endocrinology, and it continues the pattern of this summer's deals: acquirers paying for assets with near-term revenue or late-stage data rather than early platforms. For clinical development, atumelnant's Phase 3 programme is the piece to watch. CAH trials are notoriously hard to design because the goal is to normalise androgens while lowering glucocorticoid doses toward physiological levels, which requires careful titration rules and endpoint definitions. Vertex's experience in rare-disease development will now be tested in an endocrine indication with a complex dosing story.
Takeaway
Sites running Crinetics studies should expect sponsor-change notifications after closing. For the industry, three deals of roughly $10 billion or more in about a month (GSK-Nuvalent, AbbVie-Apogee and now Vertex-Crinetics) confirm that big buyers want de-risked, late-stage assets.
Sources
This item is grounded in the Vertex-Crinetics announcement of July 6, 2026, filed with the SEC, and STAT reporting.